Literature DB >> 12829843

Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host.

Isidoro Martinez1, Luis L Rodriguez, Carlos Jimenez, Steven J Pauszek, Gail W Wertz.   

Abstract

There are two major serotypes of vesicular stomatitis virus (VSV), Indiana (VSIV) and New Jersey (VSNJV). We recovered recombinant VSIVs from engineered cDNAs that contained either (i) one copy of the VSIV G gene (VSIV-G(I)); (ii) two copies of the G gene, one from each serotype (VSIV-G(NJ)G(I)); or (iii) a single copy of the G(NJ) gene instead of the G(I) gene (VSIV-G(NJ)). The recombinant viruses expressed the appropriate glycoproteins, incorporated them into virions, and were neutralized by antibodies specific for VSIV (VSIV-G(I)), VSNJV (VSIV-G(NJ)), or both (VSIV-G(NJ)G(I)), according to the glycoprotein(s) they expressed. All recombinant viruses grew to similar titers in cell culture. In mice, VSIV-G(NJ) and VSIV-G(NJ)G(I) were attenuated. However, in swine, a natural host for VSV, the G(NJ) glycoprotein-containing viruses caused more severe lesions and replicated to higher titers than the parental virus, VSIV-G(I). These observations implicate the glycoprotein as a determinant of VSV virulence in a natural host and emphasize the differences in VSV pathogenesis between mice and swine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12829843      PMCID: PMC161932          DOI: 10.1128/jvi.77.14.8039-8047.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response.

Authors:  E B Flanagan; L A Ball; G W Wertz
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Characterization of T-helper epitopes of the glycoprotein of vesicular stomatitis virus.

Authors:  C Burkhart; G Freer; R Castro; L Adorini; K H Wiesmüller; R M Zinkernagel; H Hengartner
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

3.  Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus.

Authors:  G W Wertz; V P Perepelitsa; L A Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

Review 4.  Review of the 1995 vesicular stomatitis outbreak in the western United States.

Authors:  V E Bridges; B J McCluskey; M D Salman; H S Hurd; J Dick
Journal:  J Am Vet Med Assoc       Date:  1997-09-01       Impact factor: 1.936

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  The interactionof antiody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancios; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

7.  Syncytium formation is induced in the murine neuroblastoma cell cultures which produce pathogenic type G proteins of the rabies virus.

Authors:  K Morimoto; Y J Ni; A Kawai
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

8.  Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus.

Authors:  B Dietzschold; W H Wunner; T J Wiktor; A D Lopes; M Lafon; C L Smith; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

9.  Pathogenicity and immunogenicity for mice of temperature-sensitive mutants of vesicular stomatitis virus.

Authors:  R R Wagner
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

10.  Differential effects of mutations in three domains on folding, quaternary structure, and intracellular transport of vesicular stomatitis virus G protein.

Authors:  R W Doms; A Ruusala; C Machamer; J Helenius; A Helenius; J K Rose
Journal:  J Cell Biol       Date:  1988-07       Impact factor: 10.539

View more
  26 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

2.  Relationship between within-host fitness and virulence in the vesicular stomatitis virus: correlation with partial decoupling.

Authors:  Victoria Furió; Raquel Garijo; María Durán; Andrés Moya; John C Bell; Rafael Sanjuán
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

Review 3.  Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

Authors:  Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

Review 4.  Ebola virus disease candidate vaccines under evaluation in clinical trials.

Authors:  Karen A Martins; Peter B Jahrling; Sina Bavari; Jens H Kuhn
Journal:  Expert Rev Vaccines       Date:  2016-05-27       Impact factor: 5.217

Review 5.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

6.  Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.

Authors:  Kyle S Brown; David Safronetz; Andrea Marzi; Hideki Ebihara; Heinz Feldmann
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

7.  Biological differences between vesicular stomatitis virus Indiana and New Jersey serotype glycoproteins: identification of amino acid residues modulating pH-dependent infectivity.

Authors:  Isidoro Martinez; Gail W Wertz
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 8.  Prospects for immunisation against Marburg and Ebola viruses.

Authors:  Thomas W Geisbert; Daniel G Bausch; Heinz Feldmann
Journal:  Rev Med Virol       Date:  2010-11       Impact factor: 6.989

9.  Posttranscriptional control of type I interferon genes by KSRP in the innate immune response against viral infection.

Authors:  Wei-Jye Lin; Xiaojia Zheng; Chen-Chung Lin; Jun Tsao; Xiaolin Zhu; James J Cody; Jennifer M Coleman; Roberto Gherzi; Ming Luo; Tim M Townes; Jacqueline N Parker; Ching-Yi Chen
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

10.  Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.

Authors:  Lauro Velazquez-Salinas; Shruthi Naik; Steven J Pauszek; Kah-Whye Peng; Stephen J Russell; Luis L Rodriguez
Journal:  Hum Gene Ther Clin Dev       Date:  2017-06       Impact factor: 5.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.